The global Marburg virus disease therapeutics market is expected to garner a market value of US$ 90.74 Million in 2023 and is expected to accumulate a market value of US$ 155 Million by registering a CAGR of 5.5% in the forecast period 2023 to 2033. The growth of the Marburg virus disease therapeutics market can be attributed to the increasing prevalence of the Marburg virus in different geographical regions. The demand for Marburg virus disease therapeutics registered a CAGR of 4.1% in the historical period 2018 to 2022
The Marburg virus disease market is expected to witness growth owing to the increasing prevalence of the ailment. In addition, the COVID-19 virus is fueling research and development activities for innovating therapeutics treatment for the Marburg virus diseases therapeutics market.
Data Points | Key Statistics |
---|---|
Expected Market Value (2023) | US$ 90.74 Million |
Anticipated Forecast Value (2033) | US$ 155 Million |
Projected Growth Rate (2023 to 2033) | 5.5% CAGR |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
According to market research and competitive intelligence provider Future Market Insights- the market for Marburg virus disease therapeutics reflected a value CAGR of 4.1% during the historic period, 2018 to 2022.
The similar symptoms of COVID-19 and Marburg virus diseases have created tremendous pressure on the healthcare industries, especially in the Middle East and South Africa. Thus, the demand for innovative treatments to reduce the intensity of the viruses is expected to boost the overall market in the upcoming years.
Furthermore, extensive research and development for innovating therapeutics are favoring the market's growth. Thus, the Marburg virus disease therapeutics market is expected to register a CAGR of 5.5% in the forecast period 2023 to 2033.
Exposure to the Marburg virus increases cases of contracting the virus among people
The rise in the healthcare sector globally is escalating the growth of the Marburg virus disease market. Marburg virus refers to the type of virus that belongs to the genus Marburgvirus in the family Filoviridae. This virus causes a severe viral disease that is known as Marburg virus disease (MHF), in both humans and nonhuman primates. MHF is generally characterized by systemic viral replication, abnormal inflammatory responses, and immunosuppression, similar to the Ebola virus.
Marburg can spread through human-to-human transmission via direct contact (through broken skin or mucous membranes) with the blood, secretions, organs, or other bodily fluids of infected people, and with surfaces and materials (e.g. bedding, and clothing) contaminated with these fluids. Thus, these factors are increasing the cases of the Marburg virus disease across the globe.
Increase in the prevalence of unhealthy lifestyles along with research and development efforts contributing to market growth
The surge in the number of people suffering from Marburg virus disease across the globe is one of the major factors driving the growth of the Marburg virus disease market. The rise in awareness among people regarding rare disorders and increased demand for various drugs for treating symptoms such as nausea, vomiting, chest pain, diarrhea, and jaundice, among others accelerate the market growth.
The rise in the number of clinical trials for the enhancement of drugs and therapies and the increase in the prevalence of unhealthy lifestyles of people further influence the market. Additionally, growth in awareness, the surge in investments, development in technology, change in lifestyle and rise in healthcare expenditure positively affect the Marburg virus disease market. Furthermore, advancements in medications extend profitable opportunities to the market players in the forecast period of 2023 to 2033.
Lack of awareness amongst people and the expensive nature of treatment derailing market growth
On the other hand, the high cost associated with the treatment and diagnosis is expected to obstruct market growth. Moreover, the expenditure required for investing in research and development for innovating therapeutics for treating the Marburg virus is more. This, in turn, is hampering the growth of the market.
Low awareness among people is projected to challenge the Marburg virus disease market in 2023 to 2023. Thus. Late detection of the ailment reduces the chances of receiving proper treatment to cure the ailment. All these factors are creating obstacles to the growth of the Marburg virus diseases therapeutics market.
Investment in research and development by key players favoring the market growth
North America dominates the Marburg virus disease market due to the advanced medical care system and infrastructure within the region. Moreover, the increasing prevalence of Marburg viral diseases in the region is bolstering the need for therapeutics.
Furthermore, the strong presence of key players in the region is favoring the growth of the market. Investment in research and development to innovate novel therapeutic treatment is another factor driving the growth of the market. the presence of research institutes in the USA. and Canada is bolstering the growth of the Marburg virus diseases therapeutics market in North America. Thus, North America is expected to possess a 43% market share of the Marburg virus diseases therapeutics market in North America in 2023.
Absence of Vaccines increasing dependability on Therapeutics Treatment
Owing to the increasing predominance of Ebola Virus Disease (EVD) or Ebola Virus disease and Marburg Virus Disease (MVD) or Marburg Virus disease, caused by filoviruses termed Ebola virus and Marburg virus in African countries like Guinea, the Democratic Republic of the Congo, Uganda, Angola, Kenya, and South Africa, as per updates by World Health Organization (WHO), in the Rest of the world region.
Ebola & Marburg Infections market growth is being driven by the increasing Ebola outbreaks in Guinea which then spread to Sierra Leone and Liberia and cases of Marburg Virus Disease (MVD) in Uganda and Angola. The Democratic Republic of the Congo, Kenya, and South Africa. However, as per World Health Organization (WHO), presently, there are no vaccines or antiviral treatments certified for Marburg Virus Disease (MVD) or Marburg Virus disease, which is one of the major factors hampering the growth of the Ebola & Marburg Infections Market. Thus, the Middle East and Africa are expected to possess a 39% market share for Marburg viral disease therapeutic treatment market in 2023.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Favorable reimbursement policies make hospitals a viable option for treatment
On the basis of end users, the Marburg virus diseases market is segmented into Hospitals, Specialty Clinics, Ambulatory Surgical Centres, and Others. The hospital segment is expected to hold the largest market share for Marburg virus disease therapeutics. This is owing to the availability of various treatments and diagnostics in hospitals. In addition, the presence of healthcare experts and cardiologists plays a key role in the wide usage of hospitals for the treatment of Marburg virus disease therapeutics.
In addition, initiatives by government authorities to support the treatment of Marburg virus disease therapeutics, especially in hospitals, favor the growth of the same. Moreover, reimbursement schemes and their benefits are making hospitals a go-to option for the treatment of Marburg virus disease therapeutics. Thus, the hospital segment is expected to hold a 45% market share of the Marburg virus disease therapeutics market in 2023.
Key players in the Marburg virus disease therapeutics market are Amicus Therapeutics, Inc, Alexion Pharmaceuticals, Inc, BioCryst Pharmaceuticals, Bavarian Nordic, Bio-Rad Laboratories, Inc, AlphaVax, GW Pharmaceuticals plc, Takeda Pharmaceutical Company Limited, Alexion Pharmaceuticals, Inc, Mapp Biopharmaceutical, Collaborations Pharmaceuticals, Inc, Emergent BioSolutions Inc, BioMarin and Sarepta Therapeutics, Alkido Pharma, Biofactura
Report Attribute | Details |
---|---|
Market Value in 2023 | US$ 90.74 Million |
Market Value in 2033 | US$ 155 Million |
Growth Rate | CAGR of 5.5% from 2023 to 2033 |
Base Year for Estimation | 2022 |
Historical Data | 2017 to 2022 |
Forecast Period | 2023 to 2033 |
Quantitative Units | Revenue in USD Million and CAGR from 2023 to 2033 |
Report Coverage | Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends and Pricing Analysis |
Segments Covered |
|
Regions Covered |
|
Key Countries Profiled |
|
Key Companies Profiled |
|
The marburg virus disease therapeutics market is valued at US$ 90.74 million In 2023.
The market is likely to experience a 5.5% CAGR until 2033.
The hospital segment is expected to dominate the market based on end user.
The market registered a CAGR of 4.1% from 2018 to 2022.
North America is estimated to dominate the market through 2033.
1. Executive Summary | Marburg Virus Disease Therapeutics Market 1.1. Global Market Outlook 1.2. Demand-side Trends 1.3. Supply-side Trends 1.4. Technology Roadmap Analysis 1.5. Analysis and Recommendations 2. Market Overview 2.1. Market Coverage / Taxonomy 2.2. Market Definition / Scope / Limitations 3. Market Background 3.1. Market Dynamics 3.1.1. Drivers 3.1.2. Restraints 3.1.3. Opportunity 3.1.4. Trends 3.2. Scenario Forecast 3.2.1. Demand in Optimistic Scenario 3.2.2. Demand in Likely Scenario 3.2.3. Demand in Conservative Scenario 3.3. Opportunity Map Analysis 3.4. Investment Feasibility Matrix 3.5. PESTLE and Porter’s Analysis 3.6. Regulatory Landscape 3.6.1. By Key Regions 3.6.2. By Key Countries 3.7. Regional Parent Market Outlook 4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033 4.1. Historical Market Size Value (US$ million) Analysis, 2018 to 2022 4.2. Current and Future Market Size Value (US$ million) Projections, 2023 to 2033 4.2.1. Y-o-Y Growth Trend Analysis 4.2.2. Absolute $ Opportunity Analysis 5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Drug Classification 5.1. Introduction / Key Findings 5.2. Historical Market Size Value (US$ million) Analysis By Drug Classification, 2018 to 2022 5.3. Current and Future Market Size Value (US$ million) Analysis and Forecast By Drug Classification, 2023 to 2033 5.3.1. Antiemetic 5.3.2. Nitro-glycerine 5.3.3. Loperamide 5.3.4. Antibiotics 5.3.5. Others 5.4. Y-o-Y Growth Trend Analysis By Drug Classification, 2018 to 2022 5.5. Absolute $ Opportunity Analysis By Drug Classification, 2023 to 2033 6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Route of Administration 6.1. Introduction / Key Findings 6.2. Historical Market Size Value (US$ million) Analysis By Route of Administration, 2018 to 2022 6.3. Current and Future Market Size Value (US$ million) Analysis and Forecast By Route of Administration, 2023 to 2033 6.3.1. Injectable 6.3.2. Oral 6.3.3. Parenteral 6.4. Y-o-Y Growth Trend Analysis By Route of Administration, 2018 to 2022 6.5. Absolute $ Opportunity Analysis By Route of Administration, 2023 to 2033 7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By End-Users 7.1. Introduction / Key Findings 7.2. Historical Market Size Value (US$ million) Analysis By End-Users, 2018 to 2022 7.3. Current and Future Market Size Value (US$ million) Analysis and Forecast By End-Users, 2023 to 2033 7.3.1. Hospitals 7.3.2. Specialty Clinics 7.3.3. Ambulatory Surgical Centres 7.3.4. Others 7.4. Y-o-Y Growth Trend Analysis By End-Users, 2018 to 2022 7.5. Absolute $ Opportunity Analysis By End-Users, 2023 to 2033 8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Distribution Channel 8.1. Introduction / Key Findings 8.2. Historical Market Size Value (US$ million) Analysis By Distribution Channel, 2018 to 2022 8.3. Current and Future Market Size Value (US$ million) Analysis and Forecast By Distribution Channel, 2023 to 2033 8.3.1. Hospital Pharmacy 8.3.2. Retail Pharmacy 8.3.3. Online Pharmacy 8.4. Y-o-Y Growth Trend Analysis By Distribution Channel, 2018 to 2022 8.5. Absolute $ Opportunity Analysis By Distribution Channel, 2023 to 2033 9. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region 9.1. Introduction 9.2. Historical Market Size Value (US$ million) Analysis By Region, 2018 to 2022 9.3. Current Market Size Value (US$ million) Analysis and Forecast By Region, 2023 to 2033 9.3.1. North America 9.3.2. Latin America 9.3.3. Europe 9.3.4. South Asia 9.3.5. East Asia 9.3.6. Oceania 9.3.7. Middle East and Africa (MEA) 9.4. Market Attractiveness Analysis By Region 10. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 10.1. Historical Market Size Value (US$ million) Trend Analysis By Market Taxonomy, 2018 to 2022 10.2. Market Size Value (US$ million) Forecast By Market Taxonomy, 2023 to 2033 10.2.1. By Country 10.2.1.1. The USA 10.2.1.2. Canada 10.2.2. By Drug Classification 10.2.3. By Route of Administration 10.2.4. By End-Users 10.2.5. By Distribution Channel 10.3. Market Attractiveness Analysis 10.3.1. By Country 10.3.2. By Drug Classification 10.3.3. By Route of Administration 10.3.4. By End-Users 10.3.5. By Distribution Channel 10.4. Key Takeaways 11. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 11.1. Historical Market Size Value (US$ million) Trend Analysis By Market Taxonomy, 2018 to 2022 11.2. Market Size Value (US$ million) Forecast By Market Taxonomy, 2023 to 2033 11.2.1. By Country 11.2.1.1. Brazil 11.2.1.2. Mexico 11.2.1.3. Rest of Latin America 11.2.2. By Drug Classification 11.2.3. By Route of Administration 11.2.4. By End-Users 11.2.5. By Distribution Channel 11.3. Market Attractiveness Analysis 11.3.1. By Country 11.3.2. By Drug Classification 11.3.3. By Route of Administration 11.3.4. By End-Users 11.3.5. By Distribution Channel 11.4. Key Takeaways 12. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 12.1. Historical Market Size Value (US$ million) Trend Analysis By Market Taxonomy, 2018 to 2022 12.2. Market Size Value (US$ million) Forecast By Market Taxonomy, 2023 to 2033 12.2.1. By Country 12.2.1.1. Germany 12.2.1.2. The United Kingdom 12.2.1.3. France 12.2.1.4. Spain 12.2.1.5. Italy 12.2.1.6. Rest of Europe 12.2.2. By Drug Classification 12.2.3. By Route of Administration 12.2.4. By End-Users 12.2.5. By Distribution Channel 12.3. Market Attractiveness Analysis 12.3.1. By Country 12.3.2. By Drug Classification 12.3.3. By Route of Administration 12.3.4. By End-Users 12.3.5. By Distribution Channel 12.4. Key Takeaways 13. South Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 13.1. Historical Market Size Value (US$ million) Trend Analysis By Market Taxonomy, 2018 to 2022 13.2. Market Size Value (US$ million) Forecast By Market Taxonomy, 2023 to 2033 13.2.1. By Country 13.2.1.1. India 13.2.1.2. Malaysia 13.2.1.3. Singapore 13.2.1.4. Thailand 13.2.1.5. Rest of South Asia 13.2.2. By Drug Classification 13.2.3. By Route of Administration 13.2.4. By End-Users 13.2.5. By Distribution Channel 13.3. Market Attractiveness Analysis 13.3.1. By Country 13.3.2. By Drug Classification 13.3.3. By Route of Administration 13.3.4. By End-Users 13.3.5. By Distribution Channel 13.4. Key Takeaways 14. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 14.1. Historical Market Size Value (US$ million) Trend Analysis By Market Taxonomy, 2018 to 2022 14.2. Market Size Value (US$ million) Forecast By Market Taxonomy, 2023 to 2033 14.2.1. By Country 14.2.1.1. China 14.2.1.2. Japan 14.2.1.3. South Korea 14.2.2. By Drug Classification 14.2.3. By Route of Administration 14.2.4. By End-Users 14.2.5. By Distribution Channel 14.3. Market Attractiveness Analysis 14.3.1. By Country 14.3.2. By Drug Classification 14.3.3. By Route of Administration 14.3.4. By End-Users 14.3.5. By Distribution Channel 14.4. Key Takeaways 15. Oceania Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 15.1. Historical Market Size Value (US$ million) Trend Analysis By Market Taxonomy, 2018 to 2022 15.2. Market Size Value (US$ million) Forecast By Market Taxonomy, 2023 to 2033 15.2.1. By Country 15.2.1.1. Australia 15.2.1.2. New Zealand 15.2.2. By Drug Classification 15.2.3. By Route of Administration 15.2.4. By End-Users 15.2.5. By Distribution Channel 15.3. Market Attractiveness Analysis 15.3.1. By Country 15.3.2. By Drug Classification 15.3.3. By Route of Administration 15.3.4. By End-Users 15.3.5. By Distribution Channel 15.4. Key Takeaways 16. MEA Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 16.1. Historical Market Size Value (US$ million) Trend Analysis By Market Taxonomy, 2018 to 2022 16.2. Market Size Value (US$ million) Forecast By Market Taxonomy, 2023 to 2033 16.2.1. By Country 16.2.1.1. GCC Countries 16.2.1.2. South Africa 16.2.1.3. Israel 16.2.1.4. Rest of MEA 16.2.2. By Drug Classification 16.2.3. By Route of Administration 16.2.4. By End-Users 16.2.5. By Distribution Channel 16.3. Market Attractiveness Analysis 16.3.1. By Country 16.3.2. By Drug Classification 16.3.3. By Route of Administration 16.3.4. By End-Users 16.3.5. By Distribution Channel 16.4. Key Takeaways 17. Key Countries Market Analysis 17.1. The USA 17.1.1. Pricing Analysis 17.1.2. Market Share Analysis, 2022 17.1.2.1. By Drug Classification 17.1.2.2. By Route of Administration 17.1.2.3. By End-Users 17.1.2.4. By Distribution Channel 17.2. Canada 17.2.1. Pricing Analysis 17.2.2. Market Share Analysis, 2022 17.2.2.1. By Drug Classification 17.2.2.2. By Route of Administration 17.2.2.3. By End-Users 17.2.2.4. By Distribution Channel 17.3. Brazil 17.3.1. Pricing Analysis 17.3.2. Market Share Analysis, 2022 17.3.2.1. By Drug Classification 17.3.2.2. By Route of Administration 17.3.2.3. By End-Users 17.3.2.4. By Distribution Channel 17.4. Mexico 17.4.1. Pricing Analysis 17.4.2. Market Share Analysis, 2022 17.4.2.1. By Drug Classification 17.4.2.2. By Route of Administration 17.4.2.3. By End-Users 17.4.2.4. By Distribution Channel 17.5. Germany 17.5.1. Pricing Analysis 17.5.2. Market Share Analysis, 2022 17.5.2.1. By Drug Classification 17.5.2.2. By Route of Administration 17.5.2.3. By End-Users 17.5.2.4. By Distribution Channel 17.6. The United Kingdom 17.6.1. Pricing Analysis 17.6.2. Market Share Analysis, 2022 17.6.2.1. By Drug Classification 17.6.2.2. By Route of Administration 17.6.2.3. By End-Users 17.6.2.4. By Distribution Channel 17.7. France 17.7.1. Pricing Analysis 17.7.2. Market Share Analysis, 2022 17.7.2.1. By Drug Classification 17.7.2.2. By Route of Administration 17.7.2.3. By End-Users 17.7.2.4. By Distribution Channel 17.8. Spain 17.8.1. Pricing Analysis 17.8.2. Market Share Analysis, 2022 17.8.2.1. By Drug Classification 17.8.2.2. By Route of Administration 17.8.2.3. By End-Users 17.8.2.4. By Distribution Channel 17.9. Italy 17.9.1. Pricing Analysis 17.9.2. Market Share Analysis, 2022 17.9.2.1. By Drug Classification 17.9.2.2. By Route of Administration 17.9.2.3. By End-Users 17.9.2.4. By Distribution Channel 17.10. India 17.10.1. Pricing Analysis 17.10.2. Market Share Analysis, 2022 17.10.2.1. By Drug Classification 17.10.2.2. By Route of Administration 17.10.2.3. By End-Users 17.10.2.4. By Distribution Channel 17.11. Malaysia 17.11.1. Pricing Analysis 17.11.2. Market Share Analysis, 2022 17.11.2.1. By Drug Classification 17.11.2.2. By Route of Administration 17.11.2.3. By End-Users 17.11.2.4. By Distribution Channel 17.12. Singapore 17.12.1. Pricing Analysis 17.12.2. Market Share Analysis, 2022 17.12.2.1. By Drug Classification 17.12.2.2. By Route of Administration 17.12.2.3. By End-Users 17.12.2.4. By Distribution Channel 17.13. Thailand 17.13.1. Pricing Analysis 17.13.2. Market Share Analysis, 2022 17.13.2.1. By Drug Classification 17.13.2.2. By Route of Administration 17.13.2.3. By End-Users 17.13.2.4. By Distribution Channel 17.14. China 17.14.1. Pricing Analysis 17.14.2. Market Share Analysis, 2022 17.14.2.1. By Drug Classification 17.14.2.2. By Route of Administration 17.14.2.3. By End-Users 17.14.2.4. By Distribution Channel 17.15. Japan 17.15.1. Pricing Analysis 17.15.2. Market Share Analysis, 2022 17.15.2.1. By Drug Classification 17.15.2.2. By Route of Administration 17.15.2.3. By End-Users 17.15.2.4. By Distribution Channel 17.16. South Korea 17.16.1. Pricing Analysis 17.16.2. Market Share Analysis, 2022 17.16.2.1. By Drug Classification 17.16.2.2. By Route of Administration 17.16.2.3. By End-Users 17.16.2.4. By Distribution Channel 17.17. Australia 17.17.1. Pricing Analysis 17.17.2. Market Share Analysis, 2022 17.17.2.1. By Drug Classification 17.17.2.2. By Route of Administration 17.17.2.3. By End-Users 17.17.2.4. By Distribution Channel 17.18. New Zealand 17.18.1. Pricing Analysis 17.18.2. Market Share Analysis, 2022 17.18.2.1. By Drug Classification 17.18.2.2. By Route of Administration 17.18.2.3. By End-Users 17.18.2.4. By Distribution Channel 17.19. GCC Countries 17.19.1. Pricing Analysis 17.19.2. Market Share Analysis, 2022 17.19.2.1. By Drug Classification 17.19.2.2. By Route of Administration 17.19.2.3. By End-Users 17.19.2.4. By Distribution Channel 17.20. South Africa 17.20.1. Pricing Analysis 17.20.2. Market Share Analysis, 2022 17.20.2.1. By Drug Classification 17.20.2.2. By Route of Administration 17.20.2.3. By End-Users 17.20.2.4. By Distribution Channel 17.21. Israel 17.21.1. Pricing Analysis 17.21.2. Market Share Analysis, 2022 17.21.2.1. By Drug Classification 17.21.2.2. By Route of Administration 17.21.2.3. By End-Users 17.21.2.4. By Distribution Channel 18. Market Structure Analysis 18.1. Competition Dashboard 18.2. Competition Benchmarking 18.3. Market Share Analysis of Top Players 18.3.1. By Regional 18.3.2. By Drug Classification 18.3.3. By Route of Administration 18.3.4. By End-Users 18.3.5. By Distribution Channel 19. Competition Analysis 19.1. Competition Deep Dive 19.1.1. Amicus Therapeutics, Inc. 19.1.1.1. Overview 19.1.1.2. Product Portfolio 19.1.1.3. Profitability by Market Segments 19.1.1.4. Sales Footprint 19.1.1.5. Strategy Overview 19.1.1.5.1. Marketing Strategy 19.1.2. Alexion Pharmaceuticals, Inc. 19.1.2.1. Overview 19.1.2.2. Product Portfolio 19.1.2.3. Profitability by Market Segments 19.1.2.4. Sales Footprint 19.1.2.5. Strategy Overview 19.1.2.5.1. Marketing Strategy 19.1.3. BioCryst Pharmaceuticals 19.1.3.1. Overview 19.1.3.2. Product Portfolio 19.1.3.3. Profitability by Market Segments 19.1.3.4. Sales Footprint 19.1.3.5. Strategy Overview 19.1.3.5.1. Marketing Strategy 19.1.4. Bavarian Nordic 19.1.4.1. Overview 19.1.4.2. Product Portfolio 19.1.4.3. Profitability by Market Segments 19.1.4.4. Sales Footprint 19.1.4.5. Strategy Overview 19.1.4.5.1. Marketing Strategy 19.1.5. Bio-Rad Laboratories, Inc. 19.1.5.1. Overview 19.1.5.2. Product Portfolio 19.1.5.3. Profitability by Market Segments 19.1.5.4. Sales Footprint 19.1.5.5. Strategy Overview 19.1.5.5.1. Marketing Strategy 19.1.6. AlphaVax 19.1.6.1. Overview 19.1.6.2. Product Portfolio 19.1.6.3. Profitability by Market Segments 19.1.6.4. Sales Footprint 19.1.6.5. Strategy Overview 19.1.6.5.1. Marketing Strategy 19.1.7. GW Pharmaceuticals plc. 19.1.7.1. Overview 19.1.7.2. Product Portfolio 19.1.7.3. Profitability by Market Segments 19.1.7.4. Sales Footprint 19.1.7.5. Strategy Overview 19.1.7.5.1. Marketing Strategy 19.1.8. Takeda Pharmaceutical Company Limited 19.1.8.1. Overview 19.1.8.2. Product Portfolio 19.1.8.3. Profitability by Market Segments 19.1.8.4. Sales Footprint 19.1.8.5. Strategy Overview 19.1.8.5.1. Marketing Strategy 19.1.9. Alexion Pharmaceuticals, Inc. 19.1.9.1. Overview 19.1.9.2. Product Portfolio 19.1.9.3. Profitability by Market Segments 19.1.9.4. Sales Footprint 19.1.9.5. Strategy Overview 19.1.9.5.1. Marketing Strategy 19.1.10. Mapp Biopharmaceutical 19.1.10.1. Overview 19.1.10.2. Product Portfolio 19.1.10.3. Profitability by Market Segments 19.1.10.4. Sales Footprint 19.1.10.5. Strategy Overview 19.1.10.5.1. Marketing Strategy 19.1.11. Collaborations Pharmaceuticals, Inc. 19.1.11.1. Overview 19.1.11.2. Product Portfolio 19.1.11.3. Profitability by Market Segments 19.1.11.4. Sales Footprint 19.1.11.5. Strategy Overview 19.1.11.5.1. Marketing Strategy 19.1.12. Emergent BioSolutions Inc. 19.1.12.1. Overview 19.1.12.2. Product Portfolio 19.1.12.3. Profitability by Market Segments 19.1.12.4. Sales Footprint 19.1.12.5. Strategy Overview 19.1.12.5.1. Marketing Strategy 19.1.13. BioMarin and Sarepta Therapeutics 19.1.13.1. Overview 19.1.13.2. Product Portfolio 19.1.13.3. Profitability by Market Segments 19.1.13.4. Sales Footprint 19.1.13.5. Strategy Overview 19.1.13.5.1. Marketing Strategy 19.1.14. Alkido Pharma 19.1.14.1. Overview 19.1.14.2. Product Portfolio 19.1.14.3. Profitability by Market Segments 19.1.14.4. Sales Footprint 19.1.14.5. Strategy Overview 19.1.14.5.1. Marketing Strategy 19.1.15. Biofactura 19.1.15.1. Overview 19.1.15.2. Product Portfolio 19.1.15.3. Profitability by Market Segments 19.1.15.4. Sales Footprint 19.1.15.5. Strategy Overview 19.1.15.5.1. Marketing Strategy 20. Assumptions & Acronyms Used 21. Research Methodology
Explore Healthcare Insights
View Reports